Placeholder Banner

BIO World Congress Announces 2017 GreenTech Investor Sessions

June 8, 2017

The Biotechnology Innovation Organization (BIO) today announced that eleven emerging companies will make formal presentations to investors during GreenTech Investor Sessions at the 2017 BIO World Congress on Industrial Biotechnology. The world’s largest industrial biotechnology and partnering event will be held July 23-26, 2017 at the Palais des congrès de Montréal in Montréal, Québec, Canada.

BIO’s GreenTech Investor Sessions provide emerging companies developing advanced biofuels and renewable chemical platforms to share their new technologies and value proposition through formal 15-minute presentations to an elite audience of investors and analysts. Companies were selected to present breakthrough clean technologies, bio-based consumer product strategies, proofs of concept, and extensive intellectual property coverage during the session.

The GreenTech Investor Sessions will take place on Monday July, 24:

8:30 AM:     DEINOVE

8:50 AM:     DMC Biotechnologies, Inc.

9:10 AM:     BOSK Bioproducts

10:35 AM:   S2G BioChemicals, Inc.

10:55 AM:   enEvolv

11:55 AM:   Lygos, Inc.

1:45 PM:     Mercurius Biorefining, Inc.

2:05 PM:     Kalion, Inc.

2:25 PM:     Leaf Resources, Ltd.

2:45 PM:     Industrial Microbes

3:05 PM:     Prospect Bio

 

All programs and sessions at the 2017 BIO World Congress on Industrial Biotechnology are open to members of the media. Complimentary media registration is available to editors and reporters working full time for print, broadcast or web publications with valid press credentials.

 

For more information on the conference please visit https://www.bio.org/events/bio-world-congress. For assistance, please contact worldcongress@bio.org.

Discover More
WASHINGTON, DC, April 8, 2025 – Today, the National Security Commission on Emerging Biotechnology (NSCEB), a bipartisan legislative commission established by Congress, issued its much-anticipated report detailing how the United States risks…
John Crowley, President and CEO of the Biotechnology Innovation Organization (BIO), released the following statement regarding the resignation of Peter Marks from the FDA: “Under the extraordinary leadership of Dr. Peter Marks, the FDA…
WASHINGTON (March 26, 2025) -- Today, the Biotechnology Innovation Organization (BIO) released results from a membership survey that underscores the significant, global integration of the biomedical supply chain. According to the findings, nearly 90…